Sandoz's Carol Lynch Highlights Decade Of Biosimilar Dominance And Plans For Many More Winning Years
Executive Summary
2016 marks the 10 year anniversary of the first biosimilar approval in Europe, Sandoz Inc.'s Omnitrope (somatropin), but only the first anniversary for approval of a biologic copycat drug in the US – a country that has been slow to embrace the concept. Sandoz's global head of biopharmaceuticals and oncology, Carol Lynch, explains to Scrip how the biosimilars market has developed over the last decade and what the biggest challenges have been along the way.
You may also be interested in...
Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.
Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.
Court Probes Rationale Of Biosimilars' 180-Day Notice
There was a lot of inside baseball being played at the US Court of Appeals for the Federal Circuit during April 4 oral arguments when Amgen Inc. battled Apotex Inc. over whether Congress intended for it to be mandatory for biosimilar makers to provide 180 days notice of commercial marketing (NCM) to the reference product sponsor (RPS) after the FDA licenses a copycat product.